Rev. Toxicol. (2014) 31: 149-156
Cell-based models to predict human hepatotoxicity of drugs
Gómez-Lechón MJ1,2, Tolosa L1, Donato MT1,2,3
Unidad de Hepatología Experimental. Instituto de Investigación Sanitaria La Fe (IIS La Fe). Avda. Fernando Abril Martorell, nº 106- Torre A.
46026 Valencia, Spain. 2CIBEREHD, FIS, Spain. 3Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de
Valencia, Spain.
1
Recibido 29 de Julio de 2014 / Aceptado 20 de octubre de 2014
Abstract: Drug-induced liver injury is a significant leading cause of
liver disease and post-market attrition of approved drugs. Several
hepatic cell-based models have been used for early safety risk
assessment during drug development. Their capacity to predict
hepatotoxicity depends on cells' functional performance. Cultured
hepatocytes have contributed to increase knowledge of the metabolic
patterns and mechanisms involved in drug toxicity. A major limitation
of monolayer hepatocytes is that they undergo rapid loss of hepatic
functionality over time, particularly drug metabolising capability.
The sandwich culture model promotes polarised cell surface and
stabilises hepatocyte functionality, particularly transport systems,
better than monolayer cultures. As 3D spatial organisation and
complex heterotypic cell interactions are essential for the functional
homeostasis of the liver, hepatocyte models (3D cultures, co-cultures
with NPCs and microfluidic systems) that mimic cell-cell, cellmatrix interactions and nutrient flow characteristic of the liver
microenvironment have been shown to improve the metabolic
competency of hepatocytes and have been proposed for better in vitro
predictions of drug hepatotoxicity. In addition to hepatocytes, other
cell-based models have been proposed for hepatotoxicity studies.
Hepatoma cell lines are metabolically poor compared to hepatocytes,
but offer key advantages, such as unlimited life span, reproducibility,
high availability and easy handling, which make them useful for
screening purposes. Alternatively, hepatic cell lines engineered for
stable or transient expression of key drug-metabolising enzymes have
also been used. Finally, stem cell-derived hepatocytes are emerging
in vitro systems that would provide a stable source of hepatocytes
from individuals with highly valuable particular polymorphic
characteristics for preclinical drug metabolism and toxicity
prediction of new drugs.
Key words: Co-culture, CYP-engineered cell line, hepatocytes,
hepatoma cell line, microfluidic device, sandwich culture, spheroids,
scaffold-based culture
Resumen: Modelos celulares para predecir la hepatotoxicidad
humana de fármacos. La lesión del hígado por fármacos es una de
las causas principales de enfermedad hepática y de retirada del
mercado de fármacos autorizados. Son varios los modelos de células
hepáticas utilizados durante el desarrollo de fármacos para la
valoración temprana de su seguridad. Los estudios basados en
hepatocitos cultivados han contribuido al conocimiento de los
mecanismos implicados en la toxicidad por fármacos. Una limitación
fundamental de los hepatocitos cultivados en monocapa es la pérdida
temprana de funciones hepáticas, en particular la capacidad para
metabolizar fármacos. El cultivo tipo sándwich mantiene la polaridad
de los hepatocitos y los sistemas de transporte y estabiliza su
*
e-mail: gomez_mjo@gva.es
funcionalidad mejor que el cultivo en monocapa. Puesto que la
organización espacial 3D y las interacciones celulares heterotípicas
son esenciales para la homeostasis funcional del hígado, los
hepatocitos cultivados en sistemas que reproducen las interacciones
entre células, célula-biomatriz y el flujo de nutrientes característicos
del microambiente hepático (cultivos 3D, co-cultivos con células no
parenquimales, sistemas microfluidicos) presentan mayor capacidad
metabólica y han sido propuestos para mejorar la predicción in vitro
de la hepatotoxicidad. Otras células hepáticas han sido propuestas
como alternativa a los hepatocitos para evaluar la hepatotoxicidad. Si
bien las líneas celulares de hepatoma tienen menor capacidad
metabólica que los hepatocitos, presentan ventajas clave para el
cribado de fármacos (vida ilimitada, reproducibilidad, gran
disponibilidad, fácil manejo). También se utilizan células
manipuladas para la expresión estable o transitoria de enzimas de
biotransformación. Por último, los hepatocitos procedentes de
células madre son sistemas in vitro emergentes que proporcionarían
una fuente estable de hepatocitos, a partir de individuos con
características polimórficas especiales, sumamente valiosa para la
predicción preclínica de la toxicidad de nuevos fármacos.
Palabras clave: Co-cultivos, células manipuladas genéticamente
que expresan CYPs, hepatocitos, líneas celulares de hepatomas,
cultivo en sandwich, esferoides, cultivos en soportes
tridimensionales.
Introduction
Drug-induced liver injury (DILI) is one of the most important issues
in drug development as a leading cause of discontinuation of clinical
trials and withdrawal or black box warnings of approved drugs [1].
DILI is a complex phenomenon which encompasses a spectrum of
clinical disease ranging from mild biochemical abnormalities to acute
liver failure. Hepatotoxicity can be induced by a drug itself or
indirectly by the generation of reactive metabolites (bioactivation)
(Figure 1). Toxic injury to hepatocytes is produced through multiple
mechanisms involving damage to biomolecules, alteration of cell
homeostasis/function and cell death [2].
Early safety assays during drug development are directed to reduce
potential risk of toxicity to humans, however, preclinical testing in
laboratory animals often fails to predict DILI. This poor predictivity
is attributable to several reasons, including differences in drug
metabolism and toxicity between human and experimental species
[3,4]. In this scenario, different in vitro approaches have been
explored to improve and accelerate the identification of
hepatotoxicity induced by drugs. In particular, several hepatic cellbased screening protocols have been incorporated in drug
149
Gómez-Lechón MJ, Tolosa L, Donato MT
Figure 1. Molecular events leading to drug-induced liver cell damage and death. Drugs may act directly on cellular systems or after
biotransformation by hepatocytes. In the latter case, toxicity is ultimately the balance between bioactivation and detoxification, which
determines whether a reactive metabolite elicits a toxic effect or not. There are several processes known to play a role in the molecular events
leading to irreversible cell damage and cell death by either necrosis or apoptosis.
development for early safety risk assessment [4-7]. Their capacity of
predicting in vivo hepatotoxicity depends critically on the functional
activities of the cell types used in each screening platform.
This paper presents the most valuable cell models for human
hepatotoxicity predictions including cultures of hepatocytes in
different 2D and 3D configurations as well as alternative cells to
hepatocytes such as hepatoma cell lines, CYP-engineered cells and
stem cell-derived hepatocytes. Major features, advantages and
drawbacks of the different cell models are discussed.
2D culture models of hepatocytes
For decades, 2D-cultures of hepatocytes have been widely used for in
vitro predictions of in vivo metabolic pathways and hepatotoxicity of
drugs (Figure 2). Such cell models offer the advantages of being
relatively inexpensive, reproducible, robust and convenient. Cultured
hepatocytes from different experimental species, particularly rat and
mouse, have been used. However, human hepatocytes have been
considered the gold standard in vitro model for the prediction of drug
metabolism and the assessment of hepatotoxicity [8-12], because
qualitative and quantitative interspecies differences in drugmetabolising enzymes frequently make the extrapolation of drug
metabolism and hepatotoxic effects from animal hepatocytes to man
difficult.
Monolayer cultures involve plating cells on a rigid substratum pretreated with extracellular matrix (ECM) proteins (collagen,
fibronectin or Matrigel) [11,12], where they maintain key hepaticspecific functions [8-12]. However, one major drawback of
monolayer cultures is that they undergo a rapid loss of hepatic
150
Figure 2. Hepatocyte models as tools for hepatotoxicity studies. The
models extend from well-established hepatocyte culture models
comprising a 2D monolayer and collagen-sandwich configuration,
followed by emerging complex 3D hepatic cellular models including
scaffold-based models, aggregates and microfluidic devices.
functionality over time, particularly drug metabolising capability,
which confers them a short, limited sensitivity to drug hepatotoxicity
detection [5,7,8,10,11] (Table 1).
Rev. Toxicol. (2014) 31: 149-156
Cell-based models to predict human hepatotoxicity of drugs
Table 1. Hepatocyte culture models for hepatotoxicity testing
In an attempt to maintain liver-specific functionality over longer
culture periods, a sandwich configuration was developed (Table 1).
Hepatocytes are placed between two matrix layers, traditionally
collagen or Matrigel. Maintaining hepatocytes in a sandwich culture
prevents cell viability loss, enhances secretion of organic
compounds, including urea and albumin, increases basal and induced
drug-metabolising enzyme activities, and mimics in vivo biliary
excretion rates [9,11,13,14]. Therefore, it has been suggested that the
sandwich culture model is most useful for mechanistic studies of
hepatobiliary toxicity [13,15-17]. This is important because biliary
efflux activity is inhibited by various drugs that cause iatrogenic
cholestasis, an important mechanism of DILI [18].
3D culture models of hepatocytes
As a result of the failure to predict hepatotoxic drugs in preclinical
testing using traditional hepatocyte cultures, alternative models to
phenotypically stabilise liver cell functions over a long period of time
have been developed (Figure 2). They are based in recreating
microenvironmental cues in vivo, such as a 3D architecture, multiple
cell types, cell-cell and cell-matrix interactions, soluble factors, and
dynamic nutrient flow which appear promising for drug screening
and predicting drug efficacy and toxicity in humans. 3D liver cell
models, which are amenable to routine use and high-throughput
adaptation, are particularly desirable for industrial drug discovery to
allow the realistic assessment of drug metabolism and adverse/toxic
effects [5,19]. Advantages and disadvantages of the different models
are summarized in Table 1.
Scaffold-based systems
3D cultures can be produced by embedding hepatocytes in scaffoldfree and scaffold-based systems (for a review, see [5,19]). The former
consists in suspending cells in non-adhesive hydrogels (i.e., alginate,
Matrigel, collagen, self-assembling peptides) with subsequent
polymerisation that aims to culture the hepatocytes encapsulated
within a gel [20]. Scaffold-based systems involve seeding cells on 3D
solid matrices; e.g., derived from natural materials (decellularised
liver-derived ECM) or synthetic materials ( e.g ., alginate,
polystyrene) [19,21]. While naturally derived substrates offer
advantages in biocompatibility terms, and mimic cell-matrix
interactions, synthetic scaffolds offer reproducibility and stability.
Interconnected porous networks and the pore size of 3D scaffolds are
very important for ensuring spatially uniform cell distribution, cell
migration and cell survival, which all affect the diffusion of
physiological nutrients and gases and the removal of metabolic
waste. The currently available wide range of synthetic polymers
opens up many opportunities for cell-specific tailored scaffolds. For
example, the specific affinity of hepatocytes to the galactose residue
has led to a range of synthetic scaffolds that present galactose on the
surface for improved hepatocyte adhesion and function [5,22].
Multicellular spheroids
Hepatocytes can be re-aggregated by cellular self-assembly and by
re-establishing cellular contacts to reform a 3D configuration. The
fundamental concept is that suspended isolated hepatocytes are
capable of reforming 3D tissue or spheroids if adhesion to a substrate
Rev. Toxicol. (2014) 31: 149-156
151
Gómez-Lechón MJ, Tolosa L, Donato MT
is prevented. Sustained cellular contacts are key for maintaining
hepatic differentiation and functionality in spheroids [23] (for a
review see [5]). In general, an intact actin cytoskeleton is required for
the self-assembly and differentiation of liver cell spheroids [23]. The
size of spheroids is critical since spheroids larger than 200-300 μm
are at risk of having necrotic cores since oxygen diffusion is the most
limiting parameter [5]. Spheroids can be created by various methods
[5]: (1) spontaneous self-assembly in non-adhesive wells/dishes
under static conditions; (2) agitation or microcavities; and (3) in a
hanging drop. Several reports indicate an excellent long-term
viability of human hepatocyte spheroids to preserve liver-specific
polarity, the expression and activity of phase I and phase II drugmetabolising enzymes and induction. Thus, they appear to be a
suitable model for discovering drug metabolites and long-term drug
hepatotoxicity testing, such as the repeated-dose format and highthroughput systems [24].
3D co-cultures of hepatocytes and non-parenchymal cells
The liver comprises two major cell populations, hepatocytes and nonparenchymal cells (NPCs), including endothelial, stellate and
Kupffer cells, among others. The cell-cell communication between
hepatocytes, and between hepatocytes and NPCs, and also with the
ECM, is a prerequisite for maintaining a differentiated phenotype and
required for the in vivo functional homeostasis of the liver. Moreover,
NPCs are considered important modulators of idiosyncratic
hepatotoxicity. Thus, the use of co-cultures of hepatocytes and NPCs
could further enhance the in vivo–like characteristics of a 3D culture
device and provide more predictive results.
Spheroid systems that co-culture rat hepatocytes with hepatic stellate
cells, the HSC-T6 cell line, HUVEC cells or Kupffer cells have been
developed, and it has been underlined the relevance of these complex
and long-lasting hepatic cell culture models [57]. More recently, a 3D
scaffold co-culture of human hepatocytes, stellate, Kupffer and
endothelial cells has been reported to maintain well-preserved
composition and liver function for up to 3 months [25]. Therefore,
presence of NPCs not only contribute to prolong the survival and to
improve the function of hepatocytes in culture, but can also increase
their sensitivity for DILI detection involving inflammatory mediators
[25].
Microfluidic devices
In vitro microfluidic systems have been more recently developed to
better mimic the in vivo situation due to better hepatocyte
functionality [26]. Incorporating fluid flow into 3D culture systems is
an important step for combating poor oxygen and nutrient diffusion
issues through spheroids and aggregates of cells and ECM. The
overall goal of many such efforts is to form a fully functional liver
culture model that mimics the complex in vivo architecture of a liver
lobule, and which can be used for toxicological and pharmacological
research or can be modified in a bio-artificial liver for clinical use (for
a review, see [5,19]). One real advantage is the possibility of precisely
adjusting flow rates and metabolite or drug concentrations in the
medium to mimic various physiologic conditions of blood, such as
postprandial and starvation states or circadian cycles of hormone and
metabolite concentrations. These devices preserve cell viability and
the metabolic competency of human hepatocytes at higher levels than
under static culture conditions [26-28]. The utility of these models for
toxicity testing has been explored through the prediction of in vivo
clearance rates. It has been demonstrated that the data from these
systems are more correlative with in vivo data than those deriving
from static hepatocyte cultures, and that this correlation improved
further when co-cultures were used [28,29].
Hepatoma cell lines
Although human hepatocytes are the preferred cells for drug
metabolism and hepatotoxicity studies, their scarce availability, interdonor variability, short life span, and decreased metabolic capacity
along culture time limit their routine use for screening purposes.
Several human hepatoma cell lines (e.g., HepG2, Hep3B, Huh7,
HepaRG) have been proposed as alternative cell models to
hepatocytes [30]. These cells offer key advantages over hepatocytes
such as their high availability, unlimited life span, stable phenotype,
reproducibility, and easy handling (Table 2), which make them useful
in vitro systems for drug safety assessment [30,31].
Table 2. Alternative cell sources to hepatocytes for hepatotoxicity testing
152
Rev. Toxicol. (2014) 31: 149-156
Cell-based models to predict human hepatotoxicity of drugs
Most hepatoma cell lines express many liver differentiated functions;
however, in general, they show a poor expression of drug
metabolising enzymes (CYPs, conjugating enzymes) and transport
proteins compared to primary hepatocytes [31-33]. Despite these
shortcomings, hepatoma cells have been extensively used for
cytotoxicity evaluations and to examine specific mechanisms of
toxicity. In particular, HepG2, the best characterised human
hepatoma, is one of the most currently used human cell models for
hepatotoxicity screenings. As a result of this widespread use,
exhaustive data on the effects of a huge number of compounds (model
hepatotoxins, drugs, chemicals) on many parameters indicative of
toxicity to HepG2 cells (viability, membrane integrity, cell
proliferation, ATP level, etc.) are available in the literature [6,34,35].
Recently, multiplexed high content screening and automated assays
adapted to HepG2 miniaturised culture formats (e.g., 96- or 386-well
plates) have been proposed as valuable prioritisation tools during
preclinical drug development [36,37]. These multiparametric assays
have been applied to screen large series of compounds and have
shown acceptable specificity and sensitivity to discriminate between
hepatotoxic and non-hepatotoxic drugs.
HepaRG is a recently derived hepatoma cell line that is now
considered the most promising cell model as a surrogate for human
hepatocytes in in vitro assessments. Proliferating HepaRG are
bipotent progenitor cells capable of differentiating into hepatocytelike and biliary-like cells [38]. After several weeks of culture in the
presence of DMSO, confluent monolayers of HepaRG cells
differentiate towards a hepatocyte-like phenotype with bile canaliculi
structures formation [38]. Differentiated HepaRG are now
increasingly used in hepatotoxicity studies as they show important
advantages over HepG2 and other hepatoma cells: 1) greater levels of
phase I and phase II drug-metabolising enzymes, which enables the
detection of toxic effects of reactive metabolites; 2) a polarised
expression of the hepatobiliary membrane transporters required to
identify toxicity due to the alteration of the normal function of hepatic
uptake or efflux transporters; and 3) a stable metabolic competence
for several weeks, which opens up the possibility of performing longterm repeated-dose studies for chronic toxicity assessment
[32,39,40]. However, the demanding culture requirements, long-term
differentiation protocols and high DMSO concentrations required to
maintain differentiated HepaRG cultures are major drawbacks for
their widespread use in hepatotoxicity testing [39,40].
Research efforts have been made to improve the functional capacity
of hepatoma cell lines and to promote their performance for drug
safety evaluation. Different 3D culture techniques (e.g.,
microencapsulation, cell spheroids or micro-space cell culture
systems) have been explored to improve differentiation and the
hepatic phenotype of HepG2 or HepaRG cells. Similarly to
hepatocytes, hepatoma cells grown in 3D systems have exhibited
better viability and functionality than in conventional 2D cultures
[41-43]. Therefore, these 3D organotypic cultures have been
proposed as relevant alternative systems for the more accurate
assessment of human hepatotoxicity and for metabolism-mediated
drug toxicity screenings [41-43].
CYP-transfected hepatic cell lines
Hepatotoxicity can be produced after bioactivation of the drug by
biotranformation enzymes (mainly CYPs) into reactive metabolite(s)
(Figure 1). The identification of bioactivable molecules requires the
use of metabolic competent systems capable of generating toxic
metabolites. Several cell systems based on liver-derived cell lines
engineered to express high levels of CYPs (and other drug-
metabolising enzymes) have been developed as in vitro tools for drug
metabolism and hepatotoxicity studies [30]. These metabolically
competent cells are generated by tranfection with vectors encoding
for human CYPs resulting in stable or transient expression of the
transgene [5,30]. In contrast to primary hepatocyte cultures,
transfected cell lines show high levels of CYP activities along time in
culture and offer the advantages of robustness and good experimental
reproducibility; however important limitations of these cells is that
transfection strategies can potentially alter the expression of other
hepatic functions and overexpression of a particular enzyme may
result in unbalanced metabolism and (Table 2).
Among cell lines manipulated for stable expression of drugmetabolising transgenes, those generated by the transfection of SV40
large T-antigen-immortalised human liver epithelial (THLE) cells or
HepG2 cell line are the most widely used for hepatotoxicity
assessment of bioactivable drugs [44,45]. Each CYP-transfected
THLE or HepG2 cell line stably express high levels of an individual
human CYP [45]. A study strategy based on the comparison of the
effects of a particular drug to CYP-transfected cells and to parental
non-CYP expressing cells has enabled the contribution of CYPmediated metabolism to toxicity to be explored [44-46]. However, no
more than one or two enzymes can be satisfactorily transfected into
cells, and expression levels are often too high or low when compared
to human liver/hepatocytes [46].
As an alternative, upgraded HepG2 cells generated by adenoviralmediated CYP expression have been proposed for hepatotoxicity
studies [30,47-49]. Adenoviral transduction has allowed the easily
modulated and controlled expression of multiple transgenes (up to
five CYPs) in host cells [5,48,49]. Then by selecting appropriate
mixtures of adenoviral constructs, cells customised with a particular
CYP profile (metabolic phenotype) can be produced [30]. The
versatility of these cell-based assays opens up the possibility of
making in vitro hepatotoxicity predictions to different population
groups (e.g., extensive vs poor metabolisers). However, one
limitation of this strategy is that transgene expression is transient and
a new transfection must be performed for each experiment.
Pluripotent stem cells-derived hepatocytes
Human pluripotent stem cells-derived hepatocytes are emerging as
cell-based systems that will potentially provide a stable source of
hepatocytes for reliable and high-throughput screening for the
metabolism and toxicity of candidate compounds. Different groups
have developed protocols to isolate embryonic stem cells (ESCs) and
induce them to form hepatocyte-like cells by mimicking the
developmental pathway of the liver during embryogenesis [7,50].
However, the broad variability reported by distinct laboratories of the
key enzymes implicated in drug metabolism in differentiated ESCs
implies that the application of these cells in toxicity studies is still
premature. Recent studies have focused on the 3D culture of ESCs for
toxicity testing [51].
Human induced-pluripotent stem cells (iPSCs) are an attractive
source of normal human cells because they possess self-renewing
potency and pluripotency, and can differentiate into virtually any
somatic cell type, like hepatocytes. They may provide a limitless
supply of hepatocytes for high-throughput screening with minor
batch variability from multiple individuals to improve
reproducibility and to enable testing of individual-specific toxicity
[7,52,53]. Hepatocyte-like cells differentiated from iPSCs
recapitulate many hepatic functional properties. However, current
hepatic differentiation protocols result in cells with lower levels of
Rev. Toxicol. (2014) 31: 149-156
153
Gómez-Lechón MJ, Tolosa L, Donato MT
enzyme activity and hepatic gene expression profiles than intact
human liver or human isolated hepatocytes [54,55]. Perhaps in the
future, iPSC-hepatocytes generated from individuals with different
CYP polymorphisms would be of great value for the drug metabolism
and toxicity prediction of new drugs in pre-clinical stages to enable
more successful clinical trials [53,55,56].
References
1. Norris W, Paredes AH, Lewis JH (2008) Drug-induced liver
injury in 2007. Curr Opin Gastroenterol 24: 287-297.
2. Gomez-Lechon MJ, Tolosa L, Castell JV, Donato MT (2010)
Mechanism-based selection of compounds for the development
of innovative in vitro approaches to hepatotoxicity studies in the
LIINTOP project. Toxicol In Vitro 24: 1879-1889.
3. Lewis DF, Ioannides C, Parke DV (1998) Cytochromes P450 and
species differences in xenobiotic metabolism and activation of
carcinogen. Environ Health Perspect 106: 633-641.
4. O'Brien PJ, Chan K, Silber PM (2004) Human and animal
hepatocytes in vitro with extrapolation in vivo. Chem Biol
Interact 150: 97-114.
5. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N,
Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J,
Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi
G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G,
Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R,
Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A,
Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis
GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward
A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter
HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM,
Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P,
Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M,
McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt
DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski
SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich
K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R,
Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss
TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG
(2013) Recent advances in 2D and 3D in vitro systems using
primary hepatocytes, alternative hepatocyte sources and nonparenchymal liver cells and their use in investigating
mechanisms of hepatotoxicity, cell signaling and ADME. Arch
Toxicol 87: 1315-1530.
6. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM,
Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P,
Brain P, Hougham C (2006) High concordance of drug-induced
human hepatotoxicity with in vitro cytotoxicity measured in a
novel cell-based model using high content screening. Arch
Toxicol 80: 580-604.
7. Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I (2013). Models
for liver toxicity testing. Toxicol Res (Camb) 2: 23-39.
8. Gomez-Lechon MJ, Castell JV, Donato MT (2008) An update on
metabolism studies using human hepatocytes in primary culture.
Expert Opin Drug Metab Toxicol 4: 837-854.
9. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R (2003)
Human hepatocytes as a tool for studying toxicity and drug
metabolism. Curr Drug Metab 4: 292-312.
154
10. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R (2004)
Human hepatocytes in primary culture: the choice to investigate
drug metabolism in man. Curr Drug Metab 5: 443-462.
11. Hewitt NJ, Gómez-Lechon MJ, Houston JB, Hallifax D, Brown
HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg
C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM,
Hengstler JG (2007) Primary hepatocytes: current understanding
of the regulation of metabolic enzymes and transporter proteins,
and pharmaceutical practice for the use of hepatocytes in
metabolism, enzyme induction, transporter, clearance, and
hepatotoxicity studies. Drug Metab Rev 39: 159-234.
12. LeCluyse EL (2001) Human hepatocyte culture systems for the in
vitro evaluation of cytochrome P450 expression and regulation.
Eur J Pharm Sci 13: 343-368.
13. Meng Q. Three-dimensional culture of hepatocytes for prediction
of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol
2010; 6:733-46.
14. Kienhuis AS, Wortelboer HM, Maas WJ, van Herwijnen M,
Kleinjans JC, van Delft JH, Stierum RH (2007) A sandwichcultured rat hepatocyte system with increased metabolic
competence evaluated by gene expression profiling. Toxicol In
Vitro 21: 892-901.
15. Chatterjee S, Richert L, Augustijns P, Annaert P (2014)
Hepatocyte-based in vitro model for assessment of drug-induced
cholestasis. Toxicol Appl Pharmacol 274: 124-136.
16. De Bruyn T, Chatterjee S, Fattah S, Keemink J, Nicolaï J,
Augustijns P, Annaert P (2013) Sandwich-cultured hepatocytes:
utility for in vitro exploration of hepatobiliary drug disposition
and drug-induced hepatotoxicity. Expert Opin Drug Metab
Toxicol 9: 589-616.
17. Marion TL, Perry CH, St Claire RL, Brouwer KL (2012)
Endogenous bile acid disposition in rat and human sandwichcultured hepatocytes. Toxicol Appl Pharmacol 261: 1-9.
18. Trauner M, Boyer JL (2003) Bile salt transporters: molecular
characterization, function, and regulation. Physiol Rev 83: 633671.
19. Mueller D, Heinzle E, Noor F (2013) 3D Hepatic In Vitro Models
as Tools for Toxicity Studies. Current Tissue Eng 2: 78-89.
20. Lau TT, Lee LQ, Leong W, Wang DA (2012) Formation of model
hepatocellular aggregates in a hydrogel scaffold using
degradable genipin crosslinked gelatin microspheres as cell
carriers. Biomed Mater 7:065003.
21. Kim BS, Park IK, Hoshiba T, Jiang HL, Choi YJ, Akaike T, Cho
CS (2011) Design of artificial extracellular matrices for tissue
engineering. Prog Polym Sci 36: 238-268.
22. Cho CS, Seo SJ, Park IK, Kim SH, Kim TH, Hoshiba T, Harada I,
Akaike T (2006) Galactose-carrying polymers as extracellular
matrices for liver tissue engineering. Biomaterials 27: 576-585.
23. van Zijl F, Mikulits W (2010) Hepatospheres: Three dimensional
cell cultures resemble physiological conditions of the liver.
World J Hepatol 2: 1-7.
24. Tostoes RM, Leite SB, Serra M, Jensen J, Bjorquist P, Carrondo
MJ, Brito C, Alves PM (2012) Human liver cell spheroids in
extended perfusion bioreactor culture for repeated-dose drug
testing. Hepatology 55: 1227-1236.
25. Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer
Rev. Toxicol. (2014) 31: 149-156
Cell-based models to predict human hepatotoxicity of drugs
T, Naughton B, Roth A (2013) A long-term three dimensional
liver co-culture system for improved prediction of clinically
relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol
268: 1-16.
26. Chao P, Maguire T, Novik E, Cheng KC, Yarmush ML (2009)
Evaluation of a microfluidic based cell culture platform with
primary human hepatocytes for the prediction of hepatic
clearance in human. Biochem Pharmacol 78: 625-632.
27. Goral VN, Hsieh YC, Petzold ON, Clark JS, Yuen PK, Faris RA
(2010) Perfusion-based microfluidic device for threedimensional dynamic primary human hepatocyte cell culture in
the absence of biological or synthetic matrices or coagulants. Lab
Chip 10: 3380-3386.
28. Novik E, Maguire TJ, Chao P, et al. A microfluidic hepatic
coculture platform for cell-based drug metabolism studies.
Biochem Pharmacol 2010; 79:1036-44.
29. Bhushan A, Senutovitch N, Bale SS, McCarty WJ, Hegde M,
Jindal R, Golberg I, Berk Usta O, Yarmush ML, Vernetti L,
Gough A, Bakan A, Shun TY, DeBiasio R, Lansing Taylor D
(2013) Towards a three-dimensional microfluidic liver platform
for predicting drug efficacy and toxicity in humans. Stem Cell
Res Ther 4 Suppl 1: S16.
30. Donato MT, Jover R, Gomez-Lechon MJ (2013) Hepatic cell
lines for drug hepatotoxicity testing: limitations and strategies to
upgrade their metabolic competence by gene engineering. Curr
Drug Metab 14: 946-968.
31. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ (2008) Cell
lines: a tool for in vitro drug metabolism studies. Curr Drug
Metab 9: 1-11.
32. Kanebratt KP, Andersson TB (2008) Evaluation of HepaRG cells
as an in vitro model for human drug metabolism studies. Drug
Metab Dispos 36: 1444-1452.
33. Guo L, Dial S, Shi L, Branham W, Liu J, Fang JL, Green B, Deng
H, Kaput J, Ning B (2011) Similarities and differences in the
expression of drug-metabolizing enzymes between human
hepatic cell lines and primary human hepatocytes. Drug Metab
Dispos 39: 528-538.
34. Schoonen WG, Westerink WM, de Roos JA, Débiton E (2005)
Cytotoxic effects of 100 reference compounds on Hep G2 and
HeLa cells and of 60 compounds on ECC-1 and CHO cells. I
mechanistic assays on ROS, glutathione depletion and calcein
uptake. Toxicol In Vitro 19: 505-516.
35. Schoonen WG, Stevenson JC, Westerink WM, Horbach GJ
(2012) Cytotoxic effects of 109 reference compounds on rat
H4IIE and human HepG2 hepatocytes. III: Mechanistic assays on
oxygen consumption with MitoXpress and NAD(P)H production
with Alamar Blue. Toxicol In Vitro 26: 511-525.
36. Tolosa L, Pinto S, Donato MT, Lahoz A, Castell JV, O'Connor JE,
Gómez-Lechón MJ (2012) Development of a Multiparametric
Cell-based Protocol to Screen and Classify the Hepatotoxicity
Potential of Drugs. Toxicol Sci 127: 187-198.
37. Garside H, Marcoe KF, Chesnut-Speelman J, Foster AJ, Muthas
D, Kenna JG, Warrior U, Bowes J, Baumgartner J (2014)
Evaluation of the use of imaging parameters for the detection of
compound-induced hepatotoxicity in 384-well cultures of
HepG2 cells and cryopreserved primary human hepatocytes.
Toxicol In Vitro 28: 171-181.
38. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel
F, Guguen-Guillouzo C, Guillouzo A (2006) Expression of
cytochromes P450, conjugating enzymes and nuclear receptors
in human hepatoma HepaRG cells. Drug Metab Dispos 34: 7583.
39. Rodrigues RM, Bouhifd M, Bories G, Sacco MG, Gribaldo L,
Fabbri M, Coecke S, Whelan MP (2013) Assessment of an
automated in vitro basal cytotoxicity test system based on
metabolically-competent cells. Toxicol In Vitro 27: 760-767.
40. Klein S, Mueller D, Schevchenko V, Noor F (2013) Long-term
maintenance of HepaRG cells in serum-free conditions and
application in a repeated dose study. J Appl Toxicol 2013; doi:
10.1002/jat.2929.
41. Ramaiahgari SC, den Braver MW, Herpers B, Terpstra V,
Commandeur JN, van de Water B, Price LS (2014) A 3D in vitro
model of differentiated HepG2 cell spheroids with improved
liver-like properties for repeated dose high-throughput toxicity
studies. Arch Toxicol 88: 1083-1095.
42. Mueller D, Kramer L, Hoffmann E, Klein S, Noor F (2014) 3D
organotypic HepaRG cultures as in vitro model for acute and
repeated dose toxicity studies. Toxicol In Vitro 28: 104-112.
43. Gunness P, Mueller D, Shevchenko V, Heinzle E, IngelmanSundberg M, Noor F (2013) 3D organotypic cultures of human
HepaRG cells: a tool for in vitro toxicity studies. Toxicol Sci 133:
67-78.
44. Dambach DM, Andrews BA, Moulin F (2005) New technologies
and screening strategies for hepatotoxicity: use of in vitro models.
Toxicol Pathol 33: 17-26.
45. Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna
JG (2014) A correlation between the in vitro drug toxicity of drugs
to cell lines that express human P450s and their propensity to
cause liver injury in humans. Toxicol Sci 137: 189-211.
46. Greer ML, Barber J, Eakins J, Kenna JG (2010) Cell based
approaches for evaluation of drug-induced liver injury.
Toxicology 268: 125-131.
47. Vignati L, Turlizzi E, Monaci S, Grossi, P.; Kanter, R.;
Monshouwer, M (2005) An in vitro approach to detect metabolite
toxicity due to CYP3A4-dependent bioactivation of xenobiotics.
Toxicology 216: 154-167.
48. Tolosa L, Donato MT, Perez-Cataldo G, Castell JV, GómezLechón MJ (2012) Upgrading cytochrome P450 activity in
HepG2 cells co-transfected with adenoviral vectors for drug
hepatotoxicity assessment. Toxicol In Vitro 26: 1272-1277.
49. Tolosa L, Gomez-Lechon MJ, Perez-Cataldo G, Castell JV,
Donato MT (2013) HepG2 cells simultaneously expressing five
P450 enzymes for the screening of hepatotoxicity: identification
of bioactivable drugs and the potential mechanism of toxicity
involved. Arch Toxicol 87: 1115-1127.
50. Baxter MA, Rowe C, Alder J, Harrison S, Hanley KP, Park BK,
Kitteringham NR, Goldring CE, Hanley NA (2010) Generating
hepatic cell lineages from pluripotent stem cells for drug toxicity
screening. Stem Cell Res 5: 4-22.
51. Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K,
Sakurai F, Tachibana M, Kanda K, Hayakawa T, Furue MK,
Mizuguchi H (2013) 3D spheroid culture of hESC/hiPSCderived hepatocyte-like cells for drug toxicity testing.
Rev. Toxicol. (2014) 31: 149-156
155
Gómez-Lechón MJ, Tolosa L, Donato MT
Biomaterials 34: 1781-1789.
52. Katsuda T, Sakai Y, Ochiya T (2012) Induced pluripotent stem
cell-derived hepatocytes as an alternative to human adult
hepatocytes. J Stem Cells 7:1-17.
53. Yi F, Liu GH, Izpisua Belmonte JC (2012) Human induced
pluripotent stem cells derived hepatocytes: rising promise for
disease modeling, drug development and cell therapy. Protein
Cell 3: 246-250.
55. Medine CN, Lucendo-Villarin B, Storck C, Wang F, Szkolnicka
D, Khan F, Pernagallo S, Black JR, Marriage HM, Ross JA,
Bradley M, Iredale JP, Flint O, Hay DC (2013) Developing highfidelity hepatotoxicity models from pluripotent stem cells. Stem
Cells Transl Med 2: 505-509.
56. Anson BD, Kolaja KL, Kamp TJ (2011) Opportunities for use of
human iPS cells in predictive toxicology. Clin Pharmacol Ther
89: 754-758.
54. Guguen-Guillouzo C, Corlu A, Guillouzo A (2010) Stem cellderived hepatocytes and their use in toxicology. Toxicology 270:
3-9.
156
Rev. Toxicol. (2014) 31: 149-156